全表观基因组关联研究显示自身免疫性甲状腺疾病中MDC1、KLF9和CUTA的DNA甲基化差异
该研究比较格雷夫斯病(GD)与桥本甲状腺病(HD)的全血DNA甲基化差异,在澳大利亚发现队列(GD 32例、HD 30例)和丹麦复制队列(GD 32例、HD 32例)中,识别并复制了MDC1和KLF9内的2个差异甲基化位点及CUTA内的1个差异甲基化区域,为GD与HD的不同发病提供表观遗传线索。
要点
- 在GD与HD间识别并复制了MDC1内cg06315208和KLF9内cg00049440两个差异甲基化位点。
- 识别并复制了CUTA内(6p21.32,5个CpG)的差异甲基化区域。
- 荟萃分析另识别64个差异甲基化位点和137个差异甲基化区域。
核心结论
- 研究揭示GD与HD之间存在DNA甲基化差异,可能有助于解释为何一些人发生GD而另一些人发生HD,并提供与环境风险因素的关联。
- 需要更多研究来加深对DNA甲基化在自身免疫性甲状腺疾病中作用的理解,并探讨其预后和治疗潜力。
研究设计与样本
- 全血DNA甲基化使用Infinium MethylationEPIC阵列在全基因组范围检测。
- 发现队列为澳大利亚GD患者32例和HD患者30例。
- 复制队列为丹麦GD患者32例和HD患者32例。
- 采用线性混合模型检验GD与HD间经分位数标准化的β值差异,数据随后进行荟萃分析。
- 使用Comb-p软件识别差异甲基化区域。
主要发现
- 识别并复制了GD与HD间2个差异甲基化位点:MDC1内的cg06315208和KLF9内的cg00049440(全表观基因组显著差异P < 9E-8,复制P < .05)。
- 识别并复制了CUTA内的一个差异甲基化区域(6p21.32处5个CpG)。
- 荟萃分析中另识别64个差异甲基化位点和137个差异甲基化区域。
局限性
- 需要更多研究来加深对DNA甲基化在自身免疫性甲状腺疾病中作用的理解,并探讨其预后和治疗潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Autoimmune thyroid disease (AITD) includes Graves disease (GD) and Hashimoto disease (HD), which often run in the same family. AITD etiology is incompletely understood: Genetic factors may account for up to 75% of phenotypic variance, whereas epigenetic effects (including DNA methylation [DNAm]) may contribute to the remaining variance (eg, why some individuals develop GD and others HD). OBJECTIVE: This work aimed to identify differentially methylated positions (DMPs) and differentially methylated regions (DMRs) comparing GD to HD. METHODS: Whole-blood DNAm was measured across the genome using the Infinium MethylationEPIC array in 32 Australian patients with GD and 30 with HD (discovery cohort) and 32 Danish patients with GD and 32 with HD (replication cohort). Linear mixed models were used to test for differences in quantile-normalized β values of DNAm between GD and HD and data were later meta-analyzed. Comb-p software was used to identify DMRs. RESULTS: We identified epigenome-wide significant differences (P < 9E-8) and replicated (P < .05) 2 DMPs between GD and HD (cg06315208 within MDC1 and cg00049440 within KLF9). We identified and replicated a DMR within CUTA (5 CpGs at 6p21.32). We also identified 64 DMPs and 137 DMRs in the meta-analysis. CONCLUSION: Our study reveals differences in DNAm between GD and HD, which may help explain why some people develop GD and others HD and provide a link to environmental risk factors. Additional research is needed to advance understanding of the role of DNAm in AITD and investigate its prognostic and therapeutic potential.
引用
- Lafontaine N, Shore CJ, Campbell PJ, et al. Epigenome-wide Association Study Shows Differential DNA Methylation of MDC1, KLF9, and CUTA in Autoimmune Thyroid Disease. J Clin Endocrinol Metab. 2024. PMID: 37962983. doi:10.1210/clinem/dgad659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。